Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow (NYSE:TEVA) 2026-10-09
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026
Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome
This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55